Peptide Cancer Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Peptide Cancer Vaccine Market: By Type (Multivalent Peptide Vaccine, Peptide Cocktail Type, Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Hybrid Peptide Vaccine, Others), By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others), and Geography.

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

1. Executive Summary
2. Global Peptide Cancer Vaccine Market Introduction
2.1. Global Peptide Cancer Vaccine Market – Taxonomy
2.2. Global Peptide Cancer Vaccine Market –Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By Region
3. Global Peptide Cancer Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Peptide Cancer Vaccine Market Dynamic Factors – Impact Analysis
3.6. Global Peptide Cancer Vaccine Market – Competition Landscape
4. Global Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Peptide Cancer Vaccine Market, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Multivalent Peptide Vaccine
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Peptide Cocktail Types
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Personalized Peptide Vaccine
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Peptide-Pulsed Dendritic Cancer Vaccine
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Hybrid Peptide Vaccine
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Peptide Cancer Vaccine Market, By Application, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Breast Cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Lung Cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Melanoma
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Prostate Cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Peptide Cancer Vaccine Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Region, 2022 – 2028
8. North America Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Multivalent Peptide Vaccine
8.1.2. Peptide Cocktail Type
8.1.3. Personalized Peptide Vaccine
8.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
8.1.5. Hybrid Peptide Vaccine
8.1.6. Others
8.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Melanoma
8.2.4. Prostate Cancer
8.2.5. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
8.5. North America Peptide Cancer Vaccine Market Dynamics – Trends
9. Europe Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Multivalent Peptide Vaccine
9.1.2. Peptide Cocktail Type
9.1.3. Personalized Peptide Vaccine
9.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
9.1.5. Hybrid Peptide Vaccine
9.1.6. Others
9.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Melanoma
9.2.4. Prostate Cancer
9.2.5. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
9.5. Europe Peptide Cancer Vaccine Market Dynamics – Trends
10. Asia-Pacific Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Multivalent Peptide Vaccine
10.1.2. Peptide Cocktail Type
10.1.3. Personalized Peptide Vaccine
10.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
10.1.5. Hybrid Peptide Vaccine
10.1.6. Others
10.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Melanoma
10.2.4. Prostate Cancer
10.2.5. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
10.5. Asia-Pacific Peptide Cancer Vaccine Market Dynamics – Trends
11. Latin America Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Multivalent Peptide Vaccine
11.1.2. Peptide Cocktail Type
11.1.3. Personalized Peptide Vaccine
11.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
11.1.5. Hybrid Peptide Vaccine
11.1.6. Others
11.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Breast Cancer
11.2.2. Lung Cancer
11.2.3. Melanoma
11.2.4. Prostate Cancer
11.2.5. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
11.5. Latin America Peptide Cancer Vaccine Market Dynamics – Trends
12. Middle East and Africa Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Multivalent Peptide Vaccine
12.1.2. Peptide Cocktail Type
12.1.3. Personalized Peptide Vaccine
12.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
12.1.5. Hybrid Peptide Vaccine
12.1.6. Others
12.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Breast Cancer
12.2.2. Lung Cancer
12.2.3. Melanoma
12.2.4. Prostate Cancer
12.2.5. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
12.5. MEA Peptide Cancer Vaccine Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Antigen Express
13.2.2. BioLife Science
13.2.3. Boston Biomedical
13.2.4. Enzo Life Science
13.2.5. Galena Biopharma
13.2.6. Generex Biotechnology
13.2.7. Generex Biotechnology Corporation
13.2.8. Immatics Biotechnologies
13.2.9. Immunomedics
13.2.10. ISA Pharmaceuticals
13.2.11. OncoTherapy Science
13.2.12. Sellas
13.2.13. TapImmune
13.2.14. VAXON Biotech
14. Research Methodology
15. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • Antigen Express
  • BioLife Science
  • Boston Biomedical
  • Enzo Life Science
  • Galena Biopharma
  • Generex Biotechnology
  • Generex Biotechnology Corporation
  • Immatics Biotechnologies
  • Immunomedics
  • ISA Pharmaceuticals
  • OncoTherapy Science
  • Sellas
  • TapImmune

Description

1. Executive Summary
2. Global Peptide Cancer Vaccine Market Introduction
2.1. Global Peptide Cancer Vaccine Market – Taxonomy
2.2. Global Peptide Cancer Vaccine Market –Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By Region
3. Global Peptide Cancer Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Peptide Cancer Vaccine Market Dynamic Factors – Impact Analysis
3.6. Global Peptide Cancer Vaccine Market – Competition Landscape
4. Global Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Peptide Cancer Vaccine Market, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Multivalent Peptide Vaccine
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Peptide Cocktail Types
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Personalized Peptide Vaccine
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Peptide-Pulsed Dendritic Cancer Vaccine
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Hybrid Peptide Vaccine
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Peptide Cancer Vaccine Market, By Application, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Breast Cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Lung Cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Melanoma
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Prostate Cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Peptide Cancer Vaccine Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Region, 2022 – 2028
8. North America Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Multivalent Peptide Vaccine
8.1.2. Peptide Cocktail Type
8.1.3. Personalized Peptide Vaccine
8.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
8.1.5. Hybrid Peptide Vaccine
8.1.6. Others
8.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Melanoma
8.2.4. Prostate Cancer
8.2.5. Others
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
8.5. North America Peptide Cancer Vaccine Market Dynamics – Trends
9. Europe Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Multivalent Peptide Vaccine
9.1.2. Peptide Cocktail Type
9.1.3. Personalized Peptide Vaccine
9.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
9.1.5. Hybrid Peptide Vaccine
9.1.6. Others
9.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Melanoma
9.2.4. Prostate Cancer
9.2.5. Others
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
9.5. Europe Peptide Cancer Vaccine Market Dynamics – Trends
10. Asia-Pacific Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Multivalent Peptide Vaccine
10.1.2. Peptide Cocktail Type
10.1.3. Personalized Peptide Vaccine
10.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
10.1.5. Hybrid Peptide Vaccine
10.1.6. Others
10.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Melanoma
10.2.4. Prostate Cancer
10.2.5. Others
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
10.5. Asia-Pacific Peptide Cancer Vaccine Market Dynamics – Trends
11. Latin America Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Multivalent Peptide Vaccine
11.1.2. Peptide Cocktail Type
11.1.3. Personalized Peptide Vaccine
11.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
11.1.5. Hybrid Peptide Vaccine
11.1.6. Others
11.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Breast Cancer
11.2.2. Lung Cancer
11.2.3. Melanoma
11.2.4. Prostate Cancer
11.2.5. Others
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
11.5. Latin America Peptide Cancer Vaccine Market Dynamics – Trends
12. Middle East and Africa Peptide Cancer Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Multivalent Peptide Vaccine
12.1.2. Peptide Cocktail Type
12.1.3. Personalized Peptide Vaccine
12.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
12.1.5. Hybrid Peptide Vaccine
12.1.6. Others
12.2. Application Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Breast Cancer
12.2.2. Lung Cancer
12.2.3. Melanoma
12.2.4. Prostate Cancer
12.2.5. Others
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Peptide Cancer Vaccine Market – Opportunity Analysis Index, By Type, Application, and Country, 2022 – 2028
12.5. MEA Peptide Cancer Vaccine Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Antigen Express
13.2.2. BioLife Science
13.2.3. Boston Biomedical
13.2.4. Enzo Life Science
13.2.5. Galena Biopharma
13.2.6. Generex Biotechnology
13.2.7. Generex Biotechnology Corporation
13.2.8. Immatics Biotechnologies
13.2.9. Immunomedics
13.2.10. ISA Pharmaceuticals
13.2.11. OncoTherapy Science
13.2.12. Sellas
13.2.13. TapImmune
13.2.14. VAXON Biotech
14. Research Methodology
15. Key Assumptions and Acronyms

Reviews

There are no reviews yet.

Be the first to review “Peptide Cancer Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX